Academia oncology., Год журнала: 2024, Номер 1(2)
Опубликована: Дек. 31, 2024
Язык: Английский
Cells, Год журнала: 2024, Номер 13(4), С. 345 - 345
Опубликована: Фев. 15, 2024
Ovarian cancer is a leading cause of death among women with gynecological cancers, and often diagnosed at advanced stages, to poor outcomes. This review explores genetic aspects high-grade serous, endometrioid, clear-cell ovarian carcinomas, emphasizing personalized treatment approaches. Specific mutations such as TP53 in serous BRAF/KRAS low-grade carcinomas highlight the need for tailored therapies. Varying mutation prevalence across subtypes, including BRCA1/2, PTEN, PIK3CA, CTNNB1, c-myc amplification, offers potential therapeutic targets. underscores TP53’s pivotal role advocates p53 immunohistochemical staining mutational analysis. BRCA1/2 mutations’ significance risk factors their relevance PARP inhibitor therapy are discussed, importance testing. also addresses paradoxical better prognosis linked KRAS BRAF cancer. ARID1A, PTEN alterations platinum resistance contribute landscape. Therapeutic strategies, like restoring WT function exploring PI3K/AKT/mTOR inhibitors, considered. The evolving understanding supports approaches based on individual tumor profiles. Ongoing research shows promise advancing treatments refining testing neoplastic diseases, Clinical screening tests can identify increased risk, guiding predictive risk-reducing surgery.
Язык: Английский
Процитировано
5
Trends in Immunology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
Communications Biology, Год журнала: 2025, Номер 8(1)
Опубликована: Фев. 25, 2025
Abstract Single-cell image analysis is crucial for studying drug effects on cellular morphology and phenotypic changes. Most studies focus single cell types, overlooking the complexity of interactions. Here, we establish an pipeline to extract features cancer cells cultured with fibroblasts. Using high-content imaging, analyze oncology library across five fibroblast line co-culture combinations, generating 61,440 images ∼170 million single-cell objects. Traditional phenotyping CellProfiler achieves average enrichment score 62.6% mechanisms action, while pre-trained neural networks (EfficientNetB0 MobileNetV2) reach 61.0% 62.0%, respectively. Variability in scores may reflect use multiple concentrations since not all induce significant morphological changes, as well genetic context treatment. Our study highlights nuanced drug-induced variations underscores heterogeneity ovarian lines their response complex environments.
Язык: Английский
Процитировано
0
Arhiv za farmaciju, Год журнала: 2025, Номер 75(1), С. 32 - 43
Опубликована: Янв. 1, 2025
Ovarian cancer is a leading malignancy in the female reproductive system and responsible for more deaths than any other type of affecting this system. cancers can be hereditary or sporadic. Anatomic, cellular, microenvironmental molecular features ovarian show high degree heterogeneity. Numerous genes implicated pathogenesis progression have been identified to date. The majority these act as tumour suppressor genes, oncogenes, are involved mismatch repair double-strand break mechanisms. identification mutations susceptibility could major step forward towards earlier diagnosis, personalized therapy approaches outcome monitoring. In healthy women, detecting specific mutated gene provide rationale surveillance, chemopreventive strategies, prophylactic surgery. Next-generation sequencing offers comprehensive genome analysis, which enables profound understanding new diagnostic markers therapeutic targets.
Язык: Английский
Процитировано
0
International Journal of Genomics, Год журнала: 2025, Номер 2025(1)
Опубликована: Янв. 1, 2025
Purpose: In 2014, the Society of Gynecologic Oncology (SGO) recommended universal germline testing for all patients with epithelial ovarian cancer (EOC), fallopian tube (FTC), or peritoneal (PC). Despite this position statement, genetic (GT) uptake among affected remains well below goal. The aim study is to evaluate impact an internal policy change on GT rate at a single institution. Patients and Methods: This investigation was Institutional Review Board (IRB)-approved (#22-00711) retrospective cohort which took place institution from June 2021 April 2022. assessed diagnosed EOC, FTC, PC following integrating point-of-care (POC) GT. Results: A total 272 were identified 47 excluded due nonepithelial tumors. Genetic counseling documented in 94.2% eligible (212/225) completed 90.2% (203/225). Of 22 (9.8%) who not genetically tested, 27% (6/22) offered declined. Deleterious mutations 22% (45/205) tested. these, 82.2% (37/45) BRCA, 6.8% (3/45) Lynch-associated (MSH2, MSH6, MLH1, PMS2), 4.4% (2/45) RAD51, BRIP1, 2.2% (1/45) unknown deleterious mutation reportedly different facility. Conclusion: Internal developed based analysis compliance SGO statement subsequent implementation POC led significant increase GT, indicating improvement quality medical care. rates population are markedly higher than reported literature.
Язык: Английский
Процитировано
0
Journal of Ovarian Research, Год журнала: 2025, Номер 18(1)
Опубликована: Март 21, 2025
Язык: Английский
Процитировано
0
Scientific Reports, Год журнала: 2025, Номер 15(1)
Опубликована: Апрель 15, 2025
Ovarian cancer (OC) usually progresses rapidly and is associated with high mortality, while a reliable clinical factor for OC patients to predict prognosis currently lacking. Recently, the pathogenic role of neutrophils releasing neutrophil extracellular traps (NETs) in various cancers including has gradually been recognized. The study objective was determine whether NETs-related biomarkers can be used accurately guide decision-making OC. In this study, we utilized univariate multivariate Cox regression identify key prognostic features developed model six lncRNAs, selected via LASSO regression. model's predictive capability assessed through Kaplan-Meier, ROC, analyses. To understand mechanisms, conducted GO term analysis, KEGG pathway enrichment, GSEA. We also analyzed gene mutation status, tumor load, survival rates, correlation. Additionally, compared immune functions, checkpoint expression, chemotherapy sensitivity between risk groups. Besides, validated value using test data tissues acquired from our institution. Finally, performed vitro vivo experiments confirm expression lncRNAs cellular level function GAS5. NETs-associated lncRNAs: GAS5, GBP1P1, LINC00702, LINC01933, LINC02362, ZNF687-AS1. performance, evaluated ROC curve, traditional clinicopathological features. process analysis highlighted molecular functions related antigen binding system biological processes. Variations were observed transcription regulators affecting response, inflammation, cytotoxicity, regulation. predicted IC50 values chemotherapeutic drugs (bexarotene, bicalutamide, embelin, GDC0941, thapsigargin) high- low-risk groups, finding higher patients. robustness cells, tissues, datas.
Язык: Английский
Процитировано
0
Antioxidants, Год журнала: 2024, Номер 13(7), С. 791 - 791
Опубликована: Июнь 28, 2024
Ovarian cancer (OC), known for its lethality and resistance to chemotherapy, is closely associated with iron metabolism ferroptosis-an iron-dependent cell death process, distinct from both autophagy apoptosis. Emerging evidence suggests that dysregulation of could play a crucial role in OC by inducing an imbalance the redox system, which leads ferroptosis, offering novel therapeutic approach. This review examines how disruptions metabolism, affect balance, impact progression, focusing on essential cellular functions potential as target. It highlights molecular interplay, including non-coding RNAs (ncRNAs), between explores their interactions key immune cells such macrophages T cells, well inflammation within tumor microenvironment. The also discusses glycolysis-related influences ferroptosis via reactive oxygen species. Targeting these pathways, especially through agents modulate presents promising prospects. emphasizes need deeper insights into redox-regulated system enhance therapy advocates continued research mechanisms strategies combat OC.
Язык: Английский
Процитировано
3
Molecular and Clinical Oncology, Год журнала: 2024, Номер 21(5)
Опубликована: Авг. 20, 2024
Precision medicine in breast cancer is a revolutionary approach that customizes diagnosis and treatment based on individual tumor characteristics, departing from the traditional one-size-fits-all approach. Breast diverse, with various subtypes driven by distinct genetic mutations. Understanding this diversity crucial for tailored strategies target specific vulnerabilities each tumor. Genetic testing, particularly mutations gene (BRCA) DNA repair-associated genes, helps assess hereditary risks influences decisions. Molecular subtyping guides personalized treatments, such as hormonal therapies receptor-positive tumors human epidermal growth factor receptor 2 (HER2)-targeted treatments. Targeted therapies, including those HER2-positive hormone cancers, offer more effective precise interventions. Immunotherapy, especially checkpoint inhibitors, shows promise, certain triple-negative cancer, ongoing research aiming to broaden its effectiveness. Integration of big data artificial intelligence enhances strategies, while liquid biopsies provide real-time insights into dynamics, aiding monitoring modification. Challenges persist, accessibility complexity, but emerging technologies precision prevention hope improved outcomes. Ultimately, aims optimize efficacy, minimize adverse effects enhance quality life patients cancer.
Язык: Английский
Процитировано
3
Journal of Experimental & Clinical Cancer Research, Год журнала: 2024, Номер 43(1)
Опубликована: Май 15, 2024
Abstract Over the last few decades, incidence of urogenital cancers has exhibited diverse trends influenced by screening programs and geographical variations. Among women, there been a consistent or even increased occurrence endometrial ovarian cancers; conversely, prostate cancer remains one most diagnosed malignancies, with rise in reported cases, partly due to enhanced improved efforts. Simultaneously, landscape therapeutics undergone remarkable evolution, encompassing introduction targeted therapies significant advancements traditional chemotherapy. Modern treatments aim selectively address molecular aberrations driving cancer, minimizing adverse effects on normal cells. However, chemotherapy retains its crucial role, offering broad-spectrum approach that, despite wider range side effects, indispensable treatment various cancers, often working synergistically enhance overall efficacy. For especially DNA damage response inhibitors, such as PARP have emerged promising therapeutic avenues. In BRCA -mutated inhibitors like olaparib niraparib demonstrated efficacy, leading their approval for specific indications. Similarly, patients mutations shown sensitivity these agents heralding new frontier disease management. Furthermore, progression is intricately linked hormonal regulation. Ovarian development also associated prolonged exposure estrogen, while testosterone metabolite dihydrotestosterone, can fuel growth Thus, understanding interplay between hormones, repair mechanisms hold promise exploring novel tumors. addition, it primary importance use preclinical models that mirror close possible biological genetic features patients’ tumors order effectively translate findings “from bench bedside”. summary, complex underscores need innovative approaches. Targeted therapy tailored hormone regulation might offer avenues improving management outcomes affected cancers.
Язык: Английский
Процитировано
2